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Abstract 13 
Objectives 14 
Outpatient parenteral antimicrobial therapy (OPAT) has been recognised as a useful, cost-effective and 15 
safe alternative to inpatient treatment, but no formal OPAT unit existed in Switzerland until recently. In 16 
December 2013 an OPAT unit was established at Lausanne University Hospital. We review here the 17 
experience of this new OPAT unit after 18 months of activity. 18 
Methods 19 
Patient characteristics, clinical activities and outcomes were recorded prospectively. Need and acceptance 20 
was evaluated as number of OPAT courses administered and number of patients refusing OPAT. Safety 21 
and efficacy were evaluated as: 1) adverse events linked to antimicrobials and catheters, 2) re-admission 22 
to hospital, 3) rate of treatment failures and 4) mortality.  23 
Results 24 
Over 18 months, 179 courses of OPAT were administered. Acceptance was high with only 4 patients 25 
refusing OPAT. Urinary tract infections with resistant bacteria and musculoskeletal infections were the 26 
most common diagnoses. Self-administration of antibiotics using elastomeric pumps became rapidly the 27 
most frequently used approach. 16 patients presented with adverse events linked to antimicrobials and 28 
catheters. OPAT- related readmissions occurred in 9 patients. The overall cure rate was 94%.  29 
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Conclusion 30 
This study shows that OPAT is very well accepted by patients and medical staff, even in a setting which 31 
has not used this type of treatment approach until now. Self-administration using elastomeric pumps 32 
proved to be particularly useful, safe and efficient. OPAT offers a good alternative to hospitalisation for 33 
patients presenting with infections due to resistant bacteria that cannot be treated orally anymore and for 34 
difficult to treat infections. 35 
Keywords 36 
OPAT, drug delivery, antibiotic resistance, difficult-to-treat infections 37 
Introduction 38 
Some patients require parenteral antibiotic therapy, but are well enough to return home. Outpatient 39 
parenteral antimicrobial therapy (OPAT) was first developed in the USA in the 1970s for patients with 40 
cystic fibrosis, before being adopted by many countries [1-4]. It has been recognised as a useful, cost-41 
effective and safe alternative to inpatient treatment. It is now a standard care in several countries and 42 
different national guidelines have been established [5-7]. There are various models of care for OPAT and 43 
most OPAT centres provide hospital-centred nursing programmes or services based on nurses visiting the 44 
patient’s home. A few centres have also shown that self-administration of intravenous antibiotic therapy is 45 
an effective and safe option for selected patients [8, 4]. Furthermore, use of continuous infusion of 46 
antibiotics increases the number of feasible treatments. Continuous infusion by pumps of antibiotics with 47 
a time-dependent killing mechanism is a practical option which has been described for treatment of 48 
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methicillin-susceptible Staphylococcus aureus (MSSA) infections and exacerbations of cystic fibrosis 49 
[9,10,11]. In Europe, even if many specialists feel that OPAT is required in their country, it is still 50 
underdeveloped because of lack of funding, lack of leadership and lack of coordination between hospitals 51 
and community care [12]. 52 
In the last decades, programmes to enhance care delivery on an outpatient basis in order to contain health 53 
costs have been developed in Switzerland. Administration of outpatient intravenous antibiotic therapy for 54 
patients who require parenteral therapy, but are otherwise fit enough to go home, hasn’t been used widely 55 
until recently and, to our knowledge, no official OPAT programme has been implemented in our country. 56 
In December 2013, an outpatient parenteral antibiotic treatment (OPAT) unit was initiated at Lausanne 57 
University Hospital with the goal of offering an alternative treatment programme that is equally effective 58 
and as safe as inpatient treatment. 59 
The purpose of this study was to review the experience after implementation of a new OPAT unit in the 60 
context of the Swiss Health System. Data were prospectively recorded in an OPAT registry in order to 61 
evaluate the need and acceptance, as well as the efficacy and security of the programme. 62 
Methods 63 
The OPAT service 64 
The University Hospital of Lausanne is a 1462-bed teaching hospital providing care in all major 65 
specialties. The OPAT service is led by infectious diseases physicians and a team of nurse practitioners. 66 
Patients are referred to the OPAT service by the physicians from the inpatient hospital wards, emergency 67 
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department, outpatient clinics and private hospitals. The Infectious Diseases Society of America (IDSA) 68 
guidelines are used as a basis for the organisational aspects of the unit [5, 13]. Antimicrobials are 69 
administered via peripheral catheters or peripherally inserted central catheters (PICC lines), the latter 70 
being inserted by specialist radiologists. The route of therapy (peripheral catheter vs PICC line) depends 71 
on the length of treatment and the type of administration (intermittent vs continuous drug administration), 72 
PICC lines being usually used for treatment longer than 7 days and for continuous infusions. Antibiotic 73 
administration is ensured using one of three options: 1) an OPAT nurse at the infusion centre (hospital 74 
OPAT); 2) at home with a visiting nurse (homecare OPAT); 3) the patient himself or a relative using 75 
elastomeric infusers (Easypump, B. Braun, Germany and Autofuser, Teleflex, Germany) (self OPAT). 76 
Elastomeric pumps are non-electronic pumps which deliver medication by deflation of an elastomeric 77 
membrane. They are prepared by a commercial compounder and are delivered to the infusion centre or 78 
directly to the patient’s home. In addition to being used for self-administration of intermittent infusions, 79 
elastomeric infusers are employed for continuous infusions of all antibiotics showing good stability for at 80 
least 24 hours [14, 15]. 81 
If self OPAT is considered feasible, the patient is provided with training in self-administration of 82 
antibiotics prior to discharge. Training takes place at the bedside and requires 1-2 hours of nursing time. If 83 
necessary, the patient is seen once or twice more at the OPAT clinic for additional training.  84 
Patients needing short courses of antibiotics (less than 4 days) are usually proposed to be treated at the 85 
OPAT clinic and those with limited mobility are treated at home by homecare OPAT.  86 
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Patients are reviewed by a physician and a nurse at least once a week at the OPAT clinic for symptom 87 
review, inspection and care of the intravascular device and blood monitoring. Follow-up imaging studies 88 
are done if considered necessary. 89 
Data collection 90 
Demographic data, site and nature of infection, antibiotic used, mode of administration, duration of 91 
therapy, and outcome of infection were prospectively recorded for all patients treated at the OPAT unit 92 
between December 2013 and May 2015 (18 months). Patient readmissions, adverse events related to 93 
antibiotics requiring stopping therapy, vascular access complications and death were also recorded. If a 94 
patient was, for any reason, re-hospitalized during an OPAT course and then re-enrolled without any 95 
change in diagnosis or treatment, he was included as the same OPAT episode and was not regarded as 96 
failure.  97 
Failure was defined as any evidence of relapse during antibiotic treatment, need for unanticipated surgery 98 
to control the infection or recurrence of infection within 90 days of cessation of intravenous antibiotics. 99 
The study was approved by the Ethics Committee of Vaud Canton. Patients were informed about the data 100 
collection and gave informed consent. 101 
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Results 102 
Patients 103 
Over the study period of 18 months, 237 patients were referred to the OPAT unit. The OPAT unit refused 104 
to take care of 73 patients (30%). 20 presented health conditions not suitable for ambulatory care. 16 were 105 
living too far away (> 20km). 20 were switched to oral therapy or didn’t need antibiotics anymore. 17 106 
were refused for other reasons. Only 4 patients refused OPAT. 107 
179 courses of OPAT (= OPAT episodes) were administered to 160 patients, resulting in a total of 2533 108 
days of patient care (median per patient: 9 days, range 1-78). The majority of patients were male 109 
(101/160; 63%) and the median age was 58 years (range 18-92). Over those 179 OPAT episodes, 86 110 
patients (48%) had a PICC line, 84 patients (47%) a peripheral catheter and 9 patients (5%) a portacath. 111 
The majority of patients (36%) were referred from surgical departments, followed by ambulatory care 112 
(33%) and internal medicine (31%). 113 
Diagnosis and microbiology 114 
The infectious diseases diagnoses are summarised in Figure 1. The most common primary diagnoses were 115 
urinary tract infections (58 episodes, 32%) and bone and joint infections (40 episodes, 22%).  116 
Microbiological data were available for 159 patients (88%). The most frequent microorganisms isolated 117 
were Enterobacteriaceae (59 cases, 33%). Escherichia coli was by far the most common pathogen and 118 
was found in 50 episodes (28%). Extended-spectrum β-lactamase (ESBL) producing and 119 
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fluoroquinolones-resistant E. coli were predominant (27/50 and 14/50 respectively). The second most 120 
common microorganism was Staphylococcus aureus, identified in 21 patients (12%). Methicillin-resistant 121 
S. aureus was isolated in only 3 patients. Streptococcus spp were isolated in 18 patients (10%), 122 
Staphylococcus epidermidis in 15 patients (8%) and Pseudomonas aeruginosa in 9 patients (5%). 123 
We took charge of 11 patients more than once for different infectious episodes. 8 patients presented with 124 
recurrent urinary tract infection and were colonised with resistant Enterobacteriaceae (fluoroquinolones-125 
resistant E. coli or ESBL-producing Enterobacteriaceae) or P. aeruginosa. 4 of those patients were solid 126 
organ transplant recipients. Those episodes were not related one to another and were not regarded as 127 
failure (too much time between episodes, different sites of infection, different types of bacteria).  128 
Antimicrobial therapies 129 
Antimicrobials used are shown in Figure 2. β-Lactams and glycopeptides were the most commonly used 130 
antibiotics. The most frequently prescribed agents were ceftriaxone which was used in 64 OPAT episodes 131 
for 825 days of treatment (33%), followed by ertapenem in 38 OPAT episodes (469 days of treatment, 132 
17%) and flucloxacillin in 19 OPAT episodes (308 days of treatment, 12%). Vancomycin was used in 11 133 
OPAT episodes (213 days of treatment, 9%) and teicoplanin in 6 (189 days of treatment, 8%). The 134 
hospital OPAT model was used for 82 patients (46%), self-administered OPAT for 55 patients (31%) and 135 
the homecare OPAT model for 42 patients (23%). As illustrated in Figure 3, self-administration was the 136 
preferred service model (1109 days, median per patient: 9; range 3-66) in terms of treatment-days and a 137 
significant increase of this approach was noticed during the 18 months of follow-up with 75% of patients 138 
treated this way during the last 6 months. Elastomeric pumps were used for 66 OPAT episodes (37%). 139 
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Continuous intravenous infusion was used for all antibiotics showing sufficient stability for 24 hours 140 
infusion. 42 patients were administered continuous infusions (24%) of flucloxacillin (19 episodes), 141 
cefepime (6), piperacillin-tazobactam (6), vancomycin (5), cefazolin (3), amoxicillin (2), and ceftazidime 142 
(1). 143 
Adverse events and outcome 144 
Drug-related and line-related adverse events were recorded. 16 of 179 OPAT episodes (9%) had some 145 
complication recorded. Drug-related adverse events accounted for the majority of complications and 146 
occurred in 10 patients (5.5%): drug rash n=3, thrombocytopenia n=2, acute hepatitis n=2, neutropenia 147 
n=1, acute renal insufficiency n=1, fever n=1.  148 
Three patients were readmitted to hospital for these drug-related adverse events. There were 6 line-related 149 
adverse events (3.5%), all related to PICC lines. Two were PICC line related thrombosis of the upper arm, 150 
which were treated by anticoagulation for 6 weeks. Neither of these patients had clinical evidence of 151 
pulmonary embolism. Three patients had PICC line infections. One patient presented with two distinct 152 
episodes of catheter-related bacteraemia with two different bacteria (Enterobacter aerogenes and 153 
Klebsiella pneumonia). He was readmitted to hospital for change of the PICC line for both episodes. A 154 
second patient also presented with bacteraemia and secondary infection of his knee’s spacer. He was 155 
readmitted for surgery. In both cases, antibiotics were administered at home by a nurse. The last patient 156 
was self-administering antibiotics for a Staphylococcus aureus bacteraemia. He was asymptomatic, but 157 
had control blood cultures which were positive for Enterobacter cloacae.  158 
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We did not observe any episode of Staphylococcus aureus PICC line infection or Clostridium difficile 159 
colitis during treatment or during the 3 months of follow-up after completion of treatment. 160 
Re-admission to hospital occurred in 24 OPAT episodes (12%), of which 7 were planned re-admissions 161 
and 8 unrelated to OPAT. OPAT-related re-admissions occurred in nine patients (5%) of whom two were 162 
self-administering antibiotics. Two patients were readmitted for PICC line infections, one of whom was 163 
readmitted twice. Three patients (1.6%) were readmitted because of drug-toxicity. Only three patients 164 
(1.6%) were readmitted because of treatment failure during OPAT. No patient died during OPAT.  165 
The overall cure rate was 94% with 11 patients presenting as clinical failure. Five patients needed surgical 166 
intervention for source control: three for abscess incision and two for removal of osteosynthesis material. 167 
Six patients relapsed after treatment completion. All of them had a urinary tract infection and were 168 
successfully retreated in an ambulatory setting. Outcomes are summarised in Table 1. 169 
Discussion 170 
There is a continuous pressure on hospital beds in Switzerland and the health authorities encourage a 171 
more community-based model of care in order to reduce hospital stay, reduce costs and increase 172 
availability of beds. In December 2013, an OPAT service was established at the University Hospital of 173 
Lausanne to improve ambulatory care of patients needing intravenous antimicrobials, but whose general 174 
condition allows them to go back home. This study shows that there is a real need and a high acceptance 175 
for an OPAT structure. During the first 18 months following the implementation of the service, 179 176 
patients were treated by OPAT, a number that concords with what has already been described and shows 177 
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that there is a real demand from the inpatient structure [16-18]. Furthermore, 2533 bed-days of inpatient 178 
admission have been avoided, which meets the demands of the hospital and the National Health System. 179 
These figures are a strong argument for the development of other OPAT programmes in our country. 180 
Musculoskeletal infections predominated in terms of treatment-days administered. This is not surprising 181 
considering that prosthetic surgery is increasing in an aging population as in Switzerland, and that 182 
prosthetic infections do invariably occur in a small percentage of these cases. It is to be expected that 183 
patient need for OPAT will increase in the future. Most of the patients with urinary tract infection treated 184 
by our OPAT unit had infections with ESBL producing and fluoroquinolones-resistant gram-negative 185 
bacilli. Switzerland is currently facing a strongly increasing burden of infections with resistant gram-186 
negative bacilli, which will in the future increase the need for parenteral treatment [19]. These data 187 
suggest that OPAT structures will be increasingly needed for “difficult to treat” - such as prosthetic 188 
infections, as well as for new situations like the current epidemic of resistant gram-negative bacillary 189 
infection. 190 
A characteristic of the OPAT model in Lausanne is its adaptability to a wide range of clinical situations 191 
and lengths of treatment. The fact that the OPAT service proposes three different types of administration 192 
means that any intravenous antibiotic can be administered in an ambulatory setting. Patients can be taken 193 
care of promptly by hospital OPAT if they present with a diagnosis which doesn’t need hospitalisation, 194 
like urinary tract or skin and soft tissue infections. Collaboration with home care providers has also made 195 
it possible to treat patients with limited mobility at home. The home care providers have been particularly 196 
flexible in the sense that they can ensure up to 4 antibiotic injections per day. Finally, self-administered 197 
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OPAT has been shown in our setting to be particularly useful, well accepted and safe. Patients receiving 198 
both, long and short antibiotic courses, tend to appreciate the advantages of treatment with elastomeric 199 
pumps and demonstrate good abilities for managing those treatments themselves. In addition, the 200 
organisation of the hospital discharge is facilitated when self-administration is chosen. Beside the 201 
instruction of the technique of self-administration with the pumps, this approach does not require the 202 
availability of OPAT nurses or infrastructure, except for the occasional follow-up visits. During the last 203 
six months of the study period, an important increase of self-administration was observed and currently 204 
75% of patients are treated by self-administered OPAT. This is probably explained by a concordance of 205 
different factors, such as development of clear guidelines, more confidence about the use of pumps by the 206 
team and high satisfaction of the patients. 207 
Self-administration using elastomeric pumps is likely to be interesting from an economic point of view. 208 
Elastomeric pumps cost about US$ 50 per piece and the cost to prepare them is about US$ 50 per pump 209 
excluding the drug cost [20]. One treatment day with an elastomeric pump costs therefore US$ 100, 210 
which is less than the cost of 2 hours of nursing time (US$ 80 per hour) for a home visit, or the nursing 211 
time and the cost of the treatment room to administer the antibiotics at the hospital [21]. This cost 212 
difference between self OPAT and nurse-administered OPAT is particularly important if the antibiotics 213 
have to be administered several times a day. A complete economic analysis is currently being conducted 214 
to clarify this point.   215 
Antibiotics being traditionally given in hospital, it was not known how patients and medical staff would 216 
accept this new way of treatment. Acceptance was better than expected and only 4 patients refused to be 217 
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taken care of by the OPAT unit. We noticed however that some habits are difficult to change. For instance, 218 
patients are traditionally kept at hospital until the end of fever even if their clinical situation has been 219 
stabilised. Many practitioners also don’t know that some antibiotics that require multiple doses per day, 220 
for example flucloxacillin, can be prescribed by continuous infusion, which facilitates treatment at home. 221 
Cure was achieved in 94% of patients, which is in line with the results from other published cohorts. In 222 
addition, the re-admission rate of 12% is comparable to what has already been described and only 9 of 223 
those were related to OPAT care [2, 18, 22, 23]. These figures are reassuring, considering that a relatively 224 
large proportion of the patients have been self-administering their treatment with elastomeric pumps. It 225 
can in particular be highlighted that line-related complications were rare and infections were not related to 226 
self-administration in three cases out of four.  227 
The use of elastomeric infusers for self-administration is well described and antibiotic stability tables 228 
have been published [15, 24-26]. Most antibiotic stability data have been produced by manufacturers of 229 
elastomeric pumps under standardised laboratory conditions and there can be a concern about drug-230 
stability depending on the infuser temperature under real-life conditions. Preliminary data measuring drug 231 
concentrations in the elastomeric pumps and in the plasma of patients (data not shown) seem to be 232 
reassuring, but additional such data will be collected in the future at our OPAT unit.  233 
Conclusion 234 
In conclusion, this study demonstrates that there is a real need and acceptance for an OPAT unit even in a 235 
setting that has traditionally been favouring hospital-based treatment of patients requiring intravenous 236 
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antibiotics. The data collected also prove that it is safe and efficient with low levels of failures and 237 
complications, even if a large proportion of patients were treated by self-administered OPAT using 238 
elastomeric pumps. Considering that infections due to multi-drug resistant bacteria, and difficult-to-treat 239 
such as prosthetic infection were the most frequent infections treated by the OPAT unit, and that these 240 
types of infection are likely to increase, it is probable that the need for an OPAT unit will even be more 241 
important in the future.  242 
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Fig. 1A Infections treated in terms of number of episodes (total number of episodes n = 179) 320 
321 
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Fig. 1B Infections treated in terms of treatment-days administrated (n = 2533)323 
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Fig. 2 Antimicrobials used 325 
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Fig.3 Evolution over 18 months of the service models used in term of treatment-days (n=2533) 328 
329 
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 330 
Re-admissions No (%) of patients 
Cumulative risk per 1000 
OPAT treatment-days 
Total 24 (13%) 9.5 
Planned 7 (4%) 2.8 
Unplanned 17 (9%) 6.7 
Treatment failure 3  
Adverse drug reaction 3  
PICC line infections 3  
Other medical complications 8  
   
Specific adverse events No (%) of patients 
Cumulative risk per 1000 
OPAT treatment-days 
Total 16 (9%) 6.4 
Adverse drug reaction 10 (5.5%) 4.0 
Rash 3  
Thrombopenia 2  
Acute hepatitis 2  
Neutropenia 1  
Acute renal insufficiency 1  
Fever 1  
Line-related adverse events 6 (3.5%) 2.4 
Line infections 4  
Line thrombosis 2  
   
Treatment failures No (%) of patients 
Cumulative risk per 1000 
OPAT treatment-days 
Total 11 (6%) 4.4 
Unplanned surgery 5 (2.8%) 2.0 
Surgical drainage of an abscess 3  
Removal of material of osteosynthesis  2  
Relapse after treatment completion 6 (3.2%) 2.4 
Table 1 Outcomes and adverse events 331 
